These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 23579075)

  • 1. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment.
    Gajewski TF; Woo SR; Zha Y; Spaapen R; Zheng Y; Corrales L; Spranger S
    Curr Opin Immunol; 2013 Apr; 25(2):268-76. PubMed ID: 23579075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment.
    Gajewski TF
    Semin Oncol; 2015 Aug; 42(4):663-71. PubMed ID: 26320069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trafficking of T cells into tumors.
    Slaney CY; Kershaw MH; Darcy PK
    Cancer Res; 2014 Dec; 74(24):7168-74. PubMed ID: 25477332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The genetic modification of T cells for cancer therapy: an overview of laboratory and clinical trials.
    Hwu P; Rosenberg SA
    Cancer Detect Prev; 1994; 18(1):43-50. PubMed ID: 8162605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of cancer immunotherapy with clinically available drugs that can block immunosuppressive cells.
    Kim SJ; Ha GH; Kim SH; Kang CD
    Immunol Invest; 2014; 43(6):517-34. PubMed ID: 24295450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens.
    Rosenberg SA
    Annu Rev Med; 1996; 47():481-91. PubMed ID: 8712798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Less yin, more yang: confronting the barriers to cancer immunotherapy.
    Lizée G; Cantu MA; Hwu P
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5250-5. PubMed ID: 17875752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment.
    Gajewski TF
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5256-61. PubMed ID: 17875753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing tumor T cell infiltration to enable cancer immunotherapy.
    Zhang J; Endres S; Kobold S
    Immunotherapy; 2019 Feb; 11(3):201-213. PubMed ID: 30730277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming tumor-mediated immunosuppression.
    Schlößer HA; Theurich S; Shimabukuro-Vornhagen A; Holtick U; Stippel DL; von Bergwelt-Baildon M
    Immunotherapy; 2014; 6(9):973-88. PubMed ID: 25341119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Considerations on clinical use of T cell immunotherapy for cancer.
    Plautz GE; Cohen PA; Shu S
    Arch Immunol Ther Exp (Warsz); 2003; 51(4):245-57. PubMed ID: 12956434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving homing in T cell therapy.
    Vignali D; Kallikourdis M
    Cytokine Growth Factor Rev; 2017 Aug; 36():107-116. PubMed ID: 28690108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The next challenge in cancer immunotherapy: controlling T-cell traffic to the tumor.
    Abastado JP
    Cancer Res; 2012 May; 72(9):2159-61. PubMed ID: 22549945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the tumor microenvironment by immunotherapy: part 2.
    Leibovici J; Itzhaki O; Huszar M; Sinai J
    Immunotherapy; 2011 Nov; 3(11):1385-408. PubMed ID: 22053888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune responses to human tumors: development of tumor vaccines.
    Platsoucas CD; Fincke JE; Pappas J; Jung WJ; Heckel M; Schwarting R; Magira E; Monos D; Freedman RS
    Anticancer Res; 2003; 23(3A):1969-96. PubMed ID: 12894571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Harnessing dendritic cells in cancer.
    Apetoh L; Locher C; Ghiringhelli F; Kroemer G; Zitvogel L
    Semin Immunol; 2011 Feb; 23(1):42-9. PubMed ID: 21295491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune suppression in the tumor microenvironment.
    Gajewski TF; Meng Y; Harlin H
    J Immunother; 2006; 29(3):233-40. PubMed ID: 16699366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.
    Shu S; Cochran AJ; Huang RR; Morton DL; Maecker HT
    Cancer Metastasis Rev; 2006 Jun; 25(2):233-42. PubMed ID: 16770535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hurdles to lymphocyte trafficking in the tumor microenvironment: implications for effective immunotherapy.
    Fisher DT; Chen Q; Appenheimer MM; Skitzki J; Wang WC; Odunsi K; Evans SS
    Immunol Invest; 2006; 35(3-4):251-77. PubMed ID: 16916754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving radioresponse through modification of the tumor immunological microenvironment.
    Chi KH; Wang YS; Kao SJ
    Cancer Biother Radiopharm; 2012 Feb; 27(1):6-11. PubMed ID: 22239431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.